Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Addressing investors recently at the “Russia Calling! Investment Forum,” Russian Prime Minister Vladimir Putin included biotechnology among five business sectors on which his nation and its economy are counting to deliver fast growth over the next several years. “4% is not good enough,” Putin declared in October. “We shall aim higher on the back of domestic demand, an improving investment climate, and greater investment efficiency. The ultimate goal is to diversify the economy and create high-tech jobs.” Putin spoke six months after committing Russia to growing its biopharma industry to a 5% share of the global market by the year 2020, up from just 0.2% this year. In March, Russian officials announced approval of RUB 120 billion (about $3.9 billion) toward Pharma-2020. Will Russia make it?